

New Bio-Facilities Planned

Pfizer will construct a USD \$350 MIL biosimilars manufacturing facility in Hangzhou, China; expected to serve domestic markets. The GE KuBio facility will use multiple 2,000 L single-use Xcellerex/GE bioreactors in parallel. *Source: FiercePharma, June 28, 2016*

Porton Biopharma (Porton, Wiltshire, U.K.) started construction of a 53 530m² building to be used for Erwinase (asparaginase), anthrax vaccine manufacture and also provide CMO services. *Source: Porton Biopharm PR, June 28, 2016*

A state-owned Chinese developer consortium is buying a site in South San Francisco, California, U.S. approved for a 2.25 million-square-foot biotech and life science campus and plans to start construction soon. *Source: San Francisco Business Times, June 1, 2016*

Celltrion (Song-do, Korea) is investing USD \$275 MIL to expand its bioprocessing capacity from current 140,000 L to 310,000 L by 2021. The capacity will be used for Celltrion's own biosimilars and the company's CMO projects. *Source: BioPharma-Reporter.com, May 27, 2016*

Biocon Ltd. received permissions needed for a USD \$158 MIL expansion of its current bioprocessing facility in Bangalore, India. *Source: BioPharma-Reporter, May 27, 2016*

Medicago (Quebec City, Canada), specializing in tobacco plant-expressed protein manufacture, is investing USD \$245 MIL in a new 44,000 m² production facility in Quebec, and is expected to have capacity for manufacture of 40-50 MIL doses/year of quadravalent influenza vaccines. *Source: PRNewswire, May 19, 2016*

Repligen Corp. is expanding its capacity for manufacture of pre-packed chromatography columns at the former Atoll AG (acquired by Repligen) facility in Weingarten, Germany. *Source: in-PharmaTechnologist.com, May 10, 2016*

NGM Biopharmaceuticals (S. San Francisco, California, U.S.) will be moving into a former 113,000 sq. ft. Amgen facility in S. San

Francisco completed in 2008 but never occupied by Amgen. *Source: BIOTECHSF, May 3, 2016*

Shire Ltd. (Dublin, Ireland) will construct a new bioprocessing facility in Piercetown, County Meath, Ireland, and is expected to come online in 2019, including hiring 400 staff. *Source: IDA Ireland PR, April 15, 2016*

New Facilities

Cristália Lab. (Sao Paulo, Brazil) received Brazilian approval for manufacture and marketing of Kollagenase (collagenase) for wound debridement/cleaning involving BSL-3 culture of *Clostridium histolyticum* in a 1,500 stainless steel bioreactor. *Source: Biopharma-Reporter.com, June 10, 2016*

PnuVax (Ontario, Canada) licensed XRX 001, a cell cultured yellow fever vaccine, from Xcellerex/GE, and plans a 2,000 L single-use GE FlexFactory facility. The co. expects it will be at the leading edge of a paradigm shift in vaccines manufacture (shift to modular and single-use). *Source: Biopharma-Reporter.com, June 10, 2016*

BioNua Ltd., a subsidiary of Nexvet (Dublin, Ireland), opened a 20,000 sq. ft. facility in Dublin for manufacture of veterinary products, including a monoclonal antibody for treatment of osteoarthritis in dogs. *Source: Nexvet PR, June 5, 2016*

The Industrial Biotechnology Innovation Centre (IBioIC), U.K., opened the Flexible Downstream Bioprocessing Centre (FlexBio), a downstream bioprocessing facility at Heriot-Watt University in Edinburgh, Scotland, to help co.'s test manufacturing scale-up and equipment needs ahead of a product's commercialization. *Source: Biopharma-Reporter.com, May 31, 2016*

Bristol-Myers Squibb completed a USD \$280 MIL expansion to its biopharma manufacturing facility in Devens, Massachusetts, U.S., adding 200,000 sq. ft. space, including clinical manufacturing and 200 staff. *Source: Gen. Eng. & Biotech. News, May 18, 2016*

Goodwin Biotechnology, Inc., (Plantation, Florida, U.S.) expanded its antibody-drug conjugate (ADC) manufacturing capabilities, including adding a new conjugation suite. *Source: Goodwin Biotech PR, May 18, 2016*

JHL Biotech (Taiwan) opened a GE KuBio modular facility that is fully single-use in Wuhan, China, and will be offering related CMO services, mostly for biosimilars manufacture. *Source: GE Press Release, May 10, 2016*

FUJIFILM Diosynth Biotechnologies U.S.A (Research Triangle Park, North Carolina) opened a new 3-story, 62,000 sq. ft. CMO facility housing process design and analytical departments. *Source: Outsourcing-pharma.com, May 10, 2016*

F-Star (Cambridge, U.K.), a developer of bispecific antibodies, moved into new R&D facilities at the Babraham Research Campus in Cambridge, U.K. *Source: BiopharmaReporter.com, May 10, 2016*

BioFactura Inc. (Frederick, Maryland, U.S.), a CMO primarily oriented to biosimilars development and scale-up, is expanding, including plans to hire 25 more staff. *Source: TheEagle.com, March 22, 2016*

BioINNOVATIONS

CMO Biologics (Copenhagen, Denmark) is now offering single-use manufacturing in “3Packs,” 3 x 2,000 L single-use bioreactors in parallel, and with 3 more 2,000 L bioreactors being added, will be able to offer single-use manufacturing lots up to 12,000 L. *Source: Biopharma-Reporter.com, June 3, 2016*

The U.K. Cell and Gene Therapy Catapult (CGTC) made a prediction, citing three gene therapy facilities and one cell therapy plant built in the U.K. since 2013, that the U.K. will be a major center for cellular and gene therapies development and manufacture. *Source: Biopharma-Reporter.com, May 11, 2016*

Wrap-up BioNEWS

Boehringer Ingelheim acquired the Merial veterinary subsidiary of Sanofi, including its facilities, in a deal including Sanofi receiving €4.7 billion in cash and exchange of consumer product units. Boehringer is now number one in veterinary pharmaceuticals. *Source: Boehringer Ingelheim PR, June 27, 2016*

CEVEC Pharmaceuticals GmbH (Cologne, Germany) and **Paragon Bioservices, Inc. (Baltimore, Maryland, U.S.)** will work jointly to establish CEVEC's proprietary CAP technologies as a new industry standard for the scalable production of viral gene therapy vectors. *Source: PRNewswire, June 6, 2016*

Thermo Fisher Scientific acquired FEI for USD \$4.2 BIL, including the company's high-performance electron microscopy technology. *Source: FierceBiotech, May 27, 2016*

Evercyte and VTU Technology, both in Austria, are collaborating to develop animal products-free culture media additives for Pichia (yeast) culture. *Source: Biopharma-Reporter.com, May 25, 2016*

EAG Inc. purchased and is making further investments in Analytical Bio-Chemistry Laboratories (ABC Laboratories), a CRO offering drug and biopharma analytical services. *Source: MarketWire, May 18, 2016*

Preclinical outsourcing (all pharma, not just biopharma) is expected to grow 20% annually and be a USD \$21 BIL market this year, according to a new report from Kalorama Information. *Source: Outsourcing-pharma.com, May 17, 2016*

Pall Corp. developed the HakoBio virtual reality software as a tool to help customers configure and design bioprocesses and processing suites. Equipment can be specified and the resulting facility visualized. *Source: Biopharma-reporter.com. April 27, 2016*

Alvotech will use Finesse's SmartFactory cGMP single-use biomanufacturing platform in its new fully single-use biosimilars and CMO manufacturing facility in Iceland. *Source: Contract Pharma, April 3, 2016*

TR-Pharma (Turkey) licensed 3 biosimilar products from Dr. Reddy's Labs. (India) and will be manufacturing the products for its own domestic and international marketing. *Source: Daily Sabah Business, March 20, 2016*